Quick Summary
The new NICE guideline (published October 2021) represents an important shift in how ME/CFS is recognized and treated. It acknowledges that ME/CFS is a serious medical condition, recognizes post-exertional malaise as a core symptom, and recommends against treatments like graded exercise therapy that can worsen symptoms. Instead, it calls for personalized care plans developed by a team of healthcare professionals who understand the condition.
Why It Matters
This guideline is significant because it represents a major institutional validation of patient experiences and a departure from previously recommended treatments that many patients report worsening their condition. It has potential to improve patient outcomes by promoting earlier diagnosis, preventing harm from inappropriate exercise-based interventions, and establishing compassionate, individualized care standards that should influence clinical practice in the UK and internationally.
Observed Findings
What the study reports it measured.
- ME/CFS can now be diagnosed after 3 months of illness (rather than longer periods previously required)
- Post-exertional malaise is recognized as a core diagnostic symptom
- Graded exercise therapy (GET) should not be offered as a treatment for ME/CFS
- Cognitive behavioural therapy should only be offered as supportive intervention, not as primary treatment
- People with ME/CFS often experience prejudice and stigma in healthcare settings due to lack of specific diagnostic tests
Inferred Conclusions
What the authors interpret from those results.
- Individual, tailored management by a multidisciplinary team is essential for optimal outcomes in ME/CFS
- Fixed incremental exercise programs are inappropriate and potentially harmful for people with ME/CFS
- Incorporating lived experience of patients into guideline development produces recommendations more aligned with patient outcomes
- Earlier diagnosis (at 3 months) may improve long-term health outcomes by preventing delayed or inappropriate treatments
Remaining Questions
- What specific multidisciplinary team compositions are most effective for ME/CFS management?
- Which supportive interventions beyond CBT and pacing strategies show the most benefit for patients?
- How can healthcare systems implement these guideline recommendations while managing resource constraints?
- What are the long-term health outcomes for patients diagnosed and managed according to this new guideline compared to previous approaches?
What This Study Does Not Prove
This guideline article does not present new primary research data or clinical trials proving specific treatments work better than others. It is a synthesis of existing evidence combined with expert and patient testimony, so it does not establish causal mechanisms of ME/CFS or provide quantitative efficacy data for alternative management approaches.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Kingdon, Caroline, Lowe, Adam, Shepherd, Charles, & Nacul, Luis (2022). What Primary Care Practitioners Need to Know about the New NICE Guideline for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults.. Healthcare (Basel, Switzerland). https://doi.org/10.3390/healthcare10122438
BibTeX
@article{mecfsatlas-kingdon-2022-what-primary,
author = {Kingdon, Caroline and Lowe, Adam and Shepherd, Charles and Nacul, Luis},
title = {What Primary Care Practitioners Need to Know about the New NICE Guideline for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults.},
journal = {Healthcare (Basel, Switzerland)},
year = {2022},
doi = {10.3390/healthcare10122438},
note = {PubMed: 36553962},
url = {https://www.mecfsatlas.com/evidence/kingdon-2022-what-primary},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/kingdon-2022-what-primary
Contribute
Private, reviewed by a human. Not a public comment thread.